Loading...
Loading...
CMPX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.5M |
| Gross Profit | -0.5M |
| Operating Expense | 11.9M |
| Operating I/L | -11.9M |
| Other Income/Expense | 2.0M |
| Interest Income | 2.0M |
| Pretax | -10.0M |
| Income Tax Expense | 0.5M |
| Net Income/Loss | -10.0M |
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing antibody-based therapeutics for oncology and other human diseases. The company's product candidates in the clinical stage include CTX-009, a bispecific antibody targeting Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, CTX-471, an IgG4 monoclonal antibody agonist of CD137, and CTX-8371, a bispecific inhibitor targeting PD-1 and PD-L1. These product candidates aim to address critical pathways in angiogenesis, tumor vascularization, and immune response modulation, positioning the company to generate revenue through the development and commercialization of novel therapies for cancer and other diseases.
